tradingkey.logo
tradingkey.logo

Marvel Biosciences Selects Novotech As Cro For Its Phase I Clinical Trial Of Mb-204

ReutersMar 25, 2026 11:53 AM

Marvel Biosciences Corp MRVL.V:

  • MARVEL BIOSCIENCES SELECTS NOVOTECH AS CRO FOR ITS PHASE I CLINICAL TRIAL OF MB-204

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI